114 related articles for article (PubMed ID: 36111555)
1. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022.
Kislaya I; Machado A; Magalhães S; Rodrigues AP; Franco R; Leite PP; Dias CM; Nunes B
Euro Surveill; 2022 Sep; 27(37):. PubMed ID: 36111555
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC
BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
Kislaya I; Casaca P; Borges V; Sousa C; Ferreira BI; Fonte A; Fernandes E; Dias CM; Duarte S; Almeida JP; Grenho I; Coelho L; Ferreira R; Ferreira PP; Borges CM; Isidro J; Pinto M; Menezes L; Sobral D; Nunes A; Santos D; Gonçalves AM; Vieira L; Gomes JP; Leite PP; Nunes B; Machado A; Peralta-Santos A
Emerg Infect Dis; 2023 Mar; 29(3):569-575. PubMed ID: 36737101
[TBL] [Abstract][Full Text] [Related]
6. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
Chemaitelly H; Ayoub HH; AlMukdad S; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
Nat Commun; 2022 Jun; 13(1):3082. PubMed ID: 35654888
[TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Rose AM; Nicolay N; Sandonis Martín V; Mazagatos C; Petrović G; Baruch J; Denayer S; Seyler L; Domegan L; Launay O; Machado A; Burgui C; Vaikutyte R; Niessen FA; Loghin II; Husa P; Aouali N; Panagiotakopoulos G; Tolksdorf K; Horváth JK; Howard J; Pozo F; Gallardo V; Nonković D; Džiugytė A; Bossuyt N; Demuyser T; Duffy R; Luong Nguyen LB; Kislaya I; Martínez-Baz I; Gefenaite G; Knol MJ; Popescu C; Součková L; Simon M; Michelaki S; Reiche J; Ferenczi A; Delgado-Sanz C; Lovrić Makarić Z; Cauchi JP; Barbezange C; Van Nedervelde E; O'Donnell J; Durier C; Guiomar R; Castilla J; Jonikaite I; Bruijning-Verhagen PC; Lazar M; Demlová R; Wirtz G; Amerali M; Dürrwald R; Kunstár MP; Kissling E; Bacci S; Valenciano M; ; ;
Euro Surveill; 2023 Nov; 28(47):. PubMed ID: 37997665
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
[TBL] [Abstract][Full Text] [Related]
9. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Petrone D; Bressi M; Del Manso M; Siddu A; Proietti V; Battilomo S; Menniti-Ippolito F; Popoli P; Bella A; Riccardo F; Palamara AT; Rezza G; Brusaferro S; Pezzotti P;
Vaccine; 2023 Jan; 41(1):76-84. PubMed ID: 36400660
[TBL] [Abstract][Full Text] [Related]
10. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
12. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
[TBL] [Abstract][Full Text] [Related]
14. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
Kislaya I; Sentís A; Starrfelt J; Nunes B; Martínez-Baz I; Nielsen KF; AlKerwi A; Braeye T; Fontán-Vela M; Bacci S; Meijerink H; Castilla J; Emborg HD; Hansen CH; Schmitz S; Van Evercooren I; Valenciano M; Nardone A; Nicolay N; Monge S;
Influenza Other Respir Viruses; 2023 Nov; 17(11):e13195. PubMed ID: 38019704
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.
Fabiani M; Puopolo M; Filia A; Sacco C; Mateo-Urdiales A; Spila Alegiani S; Del Manso M; D'Ancona F; Vescio F; Bressi M; Petrone D; Spuri M; Rota MC; Massari M; Da Cas R; Morciano C; Stefanelli P; Bella A; Tallon M; Proietti V; Siddu A; Battilomo S; Palamara AT; Popoli P; Brusaferro S; Rezza G; Riccardo F; Menniti Ippolito F; Pezzotti P
Expert Rev Vaccines; 2022 Jul; 21(7):975-982. PubMed ID: 35389748
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
17. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
18. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.
Nunes B; Rodrigues AP; Kislaya I; Cruz C; Peralta-Santos A; Lima J; Pinto Leite P; Sequeira D; Matias Dias C; Machado A
Euro Surveill; 2021 Sep; 26(38):. PubMed ID: 34558406
[TBL] [Abstract][Full Text] [Related]
19. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Sentís A; Kislaya I; Nicolay N; Meijerink H; Starrfelt J; Martínez-Baz I; Castilla J; Nielsen KF; Hansen CH; Emborg HD; Nardone A; Derrough T; Valenciano M; Nunes B; Monge S;
Euro Surveill; 2022 Jul; 27(30):. PubMed ID: 35904059
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
He X; Su J; Ma Y; Zhang W; Tang S
Front Immunol; 2022; 13():945930. PubMed ID: 36090988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
